(Press-News.org) CHICAGO—By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“The number of people with obesity is high and rising in the adult U.S. population. Obesity is a complex and expensive disease that has been implicated in many chronic conditions including high blood pressure, diabetes, and cardiovascular diseases,” said Kyrian Ezendu, Ph.D., an Eli Lilly and Company advisor on benefit-risk research. “Medications to treat obesity are an integral part of long-term care for people with excess weight and are recommended for people with obesity or people with overweight and at least one obesity-related condition.”
Ezendu and colleagues used data from linked electronic health records and insurance claims of people ages 18 to 80 years who were eligible for obesity medications each year from 2016 to 2021. The anti-obesity medications included phentermine-topiramate, lorcaserin, orlistat, naltrexone-bupropion, liraglutide and semaglutide.
There were approximately 1.6 million to 2.2 million adults with overweight or obesity, eligible for obesity medications in the study cohort for each year.
The overall obesity diagnosis rate based on both electronic health records and claims increased from 39.4% in 2016 to 57.2% in 2021. However, diagnosis rates from insurance claims alone were only 33.5% in 2016 and 47.3% in 2021.
Similarly, the overweight diagnosis rate grew from 18.1% in 2016 to 31.2% in 2021. Meanwhile, the claims-based rate was 15.4% in 2016 and 29.2% in 2021.
Prescribing rates for anti-obesity medications were low, according to the researchers, ranging from 0.4% to 0.5% across all years. Much like the obesity diagnosis and overweight diagnosis rates, the prescription fill rates showed an increase from 0.4% in 2016 to 0.6% in 2021.
Of note, the prescribing and fill rates from 2016 to 2021 for liraglutide doubled (from 0.1% to 0.2%). For semaglutide, it quadrupled (from 0.1% to 0.4%).
“This research demonstrates a potential gap in clinical care for people with obesity and overweight. Proper documentation of the clinical diagnosis may facilitate guideline-based treatment of obesity and overweight, particularly with the availability of several FDA-approved medications for use as an adjunct to lifestyle changes in managing obesity or overweight,” Ezendu said.
###
END
Gaps remain in identifying, treating obesity despite new treatment options
2023-06-17
ELSE PRESS RELEASES FROM THIS DATE:
Closed-loop insulin delivery systems may improve blood sugar control in children with type 1 diabetes
2023-06-17
CHICAGO—Closed-loop insulin delivery systems improve glucose control in children with type 1 diabetes without causing adverse effects, according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
A closed-loop system consists of devices that use a continuous glucose monitor and insulin pump to automatically regulate blood sugar levels for people with diabetes. The system operates “closed-loop” because it continuously monitors and adjusts (starting and stopping) insulin delivery based on the person's ...
Study finds “robotic pill” can safely deliver injectable osteoporosis drug
2023-06-17
A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel “robotic pill,” according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“We believe this study provides the first clinical evidence of safe and successful delivery of the osteoporosis drug teriparatide through an oral robotic pill,” said Arvinder Dhalla, Ph.D., who leads Clinical Development at Rani Therapeutics, the San Jose, Calif.-based company that developed the technology and funded the study. “Data from this study are very encouraging ...
Wider search needed to improve outcomes for eosinophilic food allergy
2023-06-17
The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis.
The not-so-good news: eliminating eosinophils was not enough to stop the symptoms people feel with this uncommon and severe form of food allergy. Nor did the treatment affect key measures of gut tissue health and related gene expression patterns.
These paradigm-shifting Phase 2 clinical ...
University of Montana science unlocks secrets of high-elevation pregnancies
2023-06-17
MISSOULA – Pregnancy at high elevations often is associated with low birth weights and other complications. These challenges occur in a wide range of mammals, from deer mice to human beings.
Research conducted at the University of Montana revealed some of the genetic underpinnings that allow certain highland mouse populations to protect developing fetuses in higher areas. The work was published recently in the Proceedings of the National Academy of Sciences.
“Understanding how deer mice survive and thrive at high elevations not only informs our understanding of basic evolutionary processes, it may also one ...
ASU study: Jupiter’s moon Europa may have had a slow evolution
2023-06-16
Jupiter's moon, Europa, is slightly smaller than Earth’s Moon and is one of the most promising places to search for alien life.
Amid the Jovian system, Europa is of particular interest to scientists because of the strong evidence for nutrients, water and energy to potentially provide a habitable environment for some form of life beyond Earth. In addition, Europa is believed to be made up into four layers (from surface to center): an ice shell, salt water ocean, rocky mantle, and metallic core.
Like Earth, Europa’s ...
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
2023-06-16
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Findings from the Phase Ib cohort of the KRYSTAL-1 trial, published today in the Journal of Clinical Oncology, represent the first prospective data of anti-tumor activity from a KRAS G12C inhibitor in brain metastases, providing continued evidence of the ...
ACQUIRE therapy framework shows results for intensive pediatric rehabilitation
2023-06-16
Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have demonstrated that children with a wide range of diagnoses that affect their motor function improve after receiving intensive pediatric neurorehabilitation called ACQUIRE Therapy.
The findings were published in June in Behavioral Sciences and will be included in an upcoming special issue of the journal devoted to “shifting the therapeutic paradigm for children with neuromotor disabilities to maximize development.”
“We ...
New research shows HIV can lie dormant in the brain
2023-06-16
As a part of its life cycle, the human immunodeficiency virus-1 (HIV) inserts a copy of its DNA into human immune cells. Some of these newly infected immune cells can then transition into a dormant, latent state for a long period of time, which is referred to as HIV latency.
Although current therapies, such current antiretroviral therapy (ART), can successfully block the virus from replicating further, it cannot eradicate latent HIV. If treatment is ever discontinued, the virus can rebound from latency and reignite the progression of HIV infection to AIDS.
Scientists from the HIV Cure Center at the UNC School of Medicine, University of California ...
For resistant breast cancers, two drugs may be better than one
2023-06-16
Cancer cells are even smarter than scientists previously believed, according to new CU Boulder research. When these cells are confronted with potent new drugs called CDK2 inhibitors, which are designed to prevent cancer from proliferating, they can trigger a workaround to survive the assault in as little as one to two hours.
But the study, published June 8 in the journal “Cell,” comes with a silver lining.
It reveals how cancer cells complete this adaption and shows that simultaneously administering a second, already widely ...
UMass Amherst biostatistician developing statistical tools to predict breast cancer survival and inform targeted therapies
2023-06-16
Breast cancer is a complex disease, and its progression is difficult, yet important, to predict.
While many elements may contribute to a breast cancer prognosis, University of Massachusetts Amherst biostatistician Chi Hyun Lee has zeroed in on one risk factor that has emerged for its potential to predict the disease’s progression.
Lee will use a two-year, $154,791 grant from the National Institutes of Health (NIH) in an effort to develop statistical tools that will better predict breast cancer survival rates and survival time after breast cancer recurrence.
While the project focuses on breast cancer research, the proposed statistical ...